Graphite Bio Inc GRPH:NASDAQ

RT Quote | NASDAQ | USD
Last | 4:00 PM EDT
21.48quote price arrow down-0.17 (-0.79%)
Volume
383,479
52 week range
18.45 - 34.00

...

Loading . . .
  • Open22.00
  • Day High22.49
  • Day Low20.71
  • Prev Close21.65
  • 52 Week High34.00
  • 52 Week High Date06/30/21
  • 52 Week Low18.45
  • 52 Week Low Date06/25/21

Key Stats

  • Market Cap1.248B
  • Shares Out58.08M
  • 10 Day Average Volume0.27M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open22.00
  • Day High22.49
  • Day Low20.71
  • Prev Close21.65
  • 52 Week High34.00
  • 52 Week High Date06/30/21
  • 52 Week Low18.45
  • 52 Week Low Date06/25/21
  • Market Cap1.248B
  • Shares Out58.08M
  • 10 Day Average Volume0.27M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-1.51
  • P/E (TTM)-14.19
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-22.526M
  • ROE (MRQ)-
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Graphite Bio Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Graphite Bio, Inc. is clinical-stage, gene editing company. The Company is developing a new class of therapies to cure a range of serious and life-threatening diseases. The Company's gene editing platform allows to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. The Company's lead product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that...
Perry Karsen
Chairman
Joshua Lehrer-Graiwer M.D.
Chief Executive Officer
Katherine Stultz
Chief Operating Officer
Address
279 East Grand Avenue, Suite 430
South San Francisco, CA
94080
United States